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Abstract
Anti-glucose-6-phosphate isomerase (GPI) antibodies are
known to be arthritogenic autoantibodies in K/B×N mice,
although some groups have reported that few healthy humans
retain these antibodies. The expression of Fcγ receptors (FcγRs)
is genetically regulated and has strong implications for the
development of experimental arthritis. The interaction between
immune complexes and FcγRs might therefore be involved in the
pathogenesis of some arthritic conditions. To explore the
relationship between functional polymorphisms in FcγRs
(FCGR3A-158V/F and FCGR2A-131H/R) and arthritis in
individuals positive for anti-GPI antibodies, we evaluated these
individuals with respect to FCGR genotype. Genotyping for
FCGR3A-158V/F and FCGR2A-131H/R was performed by
PCR amplification of the polymorphic site, followed by site
specific restriction digestion using the genome of 187 Japanese
patients with rheumatoid arthritis (including 23 who were anti-
GPI antibody positive) and 158 Japanese healthy individuals
(including nine who were anti-GPI antibody positive). We report
here on the association of FCGR3A-158V/F functional
polymorphism with anti-GPI antibody positive status. Eight out
of nine healthy individuals who were positive for anti-GPI
antibodies possessed the homozygous, low affinity genotype
FCGR3A-158F (odds ratio = 0.09, 95% confidence interval
0.01–0.89; P = 0.0199), and probably were 'protected' from
arthritogenic antibodies. Moreover, among those who were
homozygous for the high affinity genotype FCGR3A-158V/V,
there were clear differences in anti-human and anti-rabbit GPI
titres between patients with rheumatoid arthritis and healthy
subjects (P = 0.0027 and P = 0.0015, respectively). Our
findings provide a molecular model of the genetic regulation of
autoantibody-induced arthritis by allele-specific affinity of the
FcγRs.
Introduction
Rheumatoid arthritis (RA) is a heterogeneous autoimmune dis-
ease that is characterized by chronic inflammatory polyarthritis
[1]. One of the characteristic features of RA is the expression
of several autoantibodies. The presence of such autoantibod-
ies (e.g. rheumatoid factor [RF]), identified by screening, is
commonly used as a diagnostic marker, although the patho-
genic role played by autoantibodies in RA remains a mystery.
Fcγ receptors (FcγRs) play a pivotal role in the reaction
between immune complex and myeloid cells. Three FcγR types
have been identified in mice and humans (FcγRI, FcγRII and
FcγRIII). In mouse arthritis models, FcγRIII deficient hosts
exhibit resistance to collagen type II induced arthritis and anti-
glucose-6-phosphate isomerase (GPI) antibody induced
arthritis [2,3], suggesting that FcγRIII is indispensible in
autoantibody dependent arthritis. In humans FcγRs are
encoded by eight genes, and the genes encoding the low
affinity FcγRs (FCGR2A, FCGR3A, FCGR2C, FCGR3B andR1183
AP = alkaline phosphatase; bp = base pairs; ELISA = enzyme-linked immunosorbent assay; FcγR = Fcγ receptor; GPI = glucose-6-phosphate iso-
merase; GST = gluthathione-S-transferase; OD = optical density; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; RA = rheu-
matoid arthritis; RF = rheumatoid factor.
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R1184FCGR2B) are located within a gene cluster on chromosome
1q22-23. Of these FcγRs, FcγRIIIa and FcγRIIa are known to
be stimulatory receptors. Various genetic polymorphisms of
these receptors were reported to be associated with several
autoimmune diseases [4,5], one of which is a polymorphism in
FCGR3A, with either a phenylalanine (F) or a valine (V) at
amino acid position 158 [6,7]. Moreover, based on findings
from a co-crystalization study with IgG1 and FcγRIIIa [8], this
residue directly interacts with the lower hinge region of IgG1,
suggesting strong binding between IgG1 and FcγRIIIa-158V
on both natural killer cells and macrophages. For FCGR2A
genes, a polymorphism at position 131 (with either histidine
[H] or arginine [R]) alters the ability of the receptor to bind to
certain IgG subclasses [9,10].
In RA patients, FCG3A-158V/F polymorphisms were reported
to be frequent in UK Caucasian, North Indian and Pakistani
individuals [11,12], but not in Japanese, Spanish and French
individuals [13-15]. The reason for these differences between
populations is unknown, although it is possible that they might
depend on the prevalence in these populations of patients
with autoantibody related forms of RA, in particular the preva-
lence of those who have pathogenic autoantibodies that
directly interact with FcγRs (especially FcγRIIIa).
Anti-GPI antibodies are candidate arthritogenic antibodies. In
K/B×N mice, polyclonal or two monoclonal anti-GPI antibod-
ies induced arthritis in several strains of mice [16]. Moreover,
FcγRIII deficient mice were resistant to anti-GPI antibody
induced arthritis [3]. Another recent report [17] also confirmed
that immune complex and FcγRIII are essential initiators of
arthritis through sequential activation of effector cells, thus giv-
ing antibodies access into the joint. In human RA, anti-GPI
antibodies have frequently been detected in patients with
aggressive forms of arthritis [18,19], and their levels corre-
lated significantly with extra-articular manifestations such as
rheumatoid nodules, rheumatoid vasculitis and Felty's syn-
drome [20]. Moreover, a modest association of homozygosity
for the FCGR3A-158V allele with RA in the nodular phenotype
was suggested by Morgan and coworkers [11], suggesting
the presence of a link between anti-GPI antibodies and
FCGR3A allele. However, whether anti-GPI antibody positive
status correlates with RA is a matter of controversy [18-22]. In
our assay few healthy individuals retained anti-GPI antibodies;
however, we do not know whether these protective pheno-
types are associated with certain human gene polymorphisms.
In order to determine the relationship between functional pol-
ymorphisms of FCGR and possible arthritogenic anti-GPI anti-
bodies in human conditions, we examined the correlation of
these polymorphisms with anti-GPI positivity.
Materials and methods
Patients
The study was approved by the local ethics review committee
and written informed consent was obtained from all partici-
pants. Blood samples were collected from 187 Japanese
patients with RA (mean age 46 ± 17 years; 33 females; mean
disease duration 12.9 years [range 1–46 years]) including four
with vasculitis and three with Felty's syndrome. These patients,
randomly selected from among patients visiting the clinic,
were followed at University of Tsukuba Hospital. The diagnosis
of RA was based on the criteria presented by the American
College of Rheumatology [23]. In addition, 158 Japanese vol-
unteers (mean age 30 ± 9 years; 105 females) were recruited
from our institute to serve as a healthy comparison group. All
healthy individuals were free of rheumatic disease symptoms,
and derived from the same geographic locations.
Enzyme-linked immunosorbent assay for GPI
In order to select anti-GPI antibody positive patients, we used
recombinant human GPI (described in detail previously [18])
or rabbit muscle GPI (Sigma, St Louis, MO, USA). Both anti-
gens were used at 5 µg/ml (diluted in phosphate-buffered
saline [PBS]) to coat microtitre plates (12 hours, 4°C). After
washing twice with washing buffer (0.05% Tween 20 in PBS),
Block Ace (diluted 1/4 in 1 × PBS; Dainippon Pharmaceuti-
cals, Osaka, Japan) was used for saturation (30 min at 37°C).
After two washes, sera (diluted 1/50) were added and the
plates were incubated for 12 hours at 4°C. After washing,
alkaline phosphatase (AP)-conjugated anti-human IgG (Fc
fragment specific; Jackson Immuno Research, West Grove,
PA, USA) was added to the plate (dilution 1/1000, for 1 hour
at room temperature). After three washes, colour was devel-
oped with AP reaction solution (containing 9.6% diethanol
amine, 0.25 mmol/l MgCl2; pH 9.8) with AP substrate tablets
(Sigma; one AP tablet per 5 ml AP reaction solution). Plates
were incubated for 1 hour at room temperature, and the optical
density (OD) was measured by plate spectrophotometry at
405 nm. Determinations were performed in triplicate and
standardized between experiments by reference to a highly
positive human anti-GPI serum. The primary reading was proc-
essed by subtracting OD readings of control wells (coated
with gluthathione-S-transferase (GST) and Block Ace for
recombinant GPI–GST and rabbit GPI, respectively). The cut-
off OD was calculated from the ELISA reactions of 158
healthy Japanese donors. Those who were double positive to
both antigens were considered anti-GPI antibody positive.
Because we used two antigens for the discrimination, the cut-
off OD (mean value + 1 standard deviation) was 0.98 for
human recombinant GPI and 0.64 for rabbit native GPI.
Genomic DNA was isolated from 0.5 ml anticoagulated
peripheral blood, from 187 RA patients and 158 healthy indi-
viduals, by using DNA QuickII DNA purification kit (Dainippon
Pharmaceuticals, Osaka, Japan). FcγR polymorphisms
(FCGR3A-158V/F) were identified, as described by Koene
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R1185and coworkers [6], using a nested PCR followed by allele spe-
cific restriction enzyme digestion. For homozygous FcγRIIIA-
158F patients only one undigested band (94 bp) was visible.
Three bands (94 bp, 61 bp and 33 bp) were seen in hetero-
zygous individuals, whereas for homozygous FcγRIIIA-158V
patients only two digested bands (61 bp and 33 bp) were
detected (Fig. 1a). These genotyping findings were confirmed
by direct sequencing in some individuals.
FcγRIIA-131H/R genotyping
Genotyping of FcγRIIA-131H/R also consisted of PCR fol-
lowed by an allele specific restriction enzyme digestion, in
accordance with the method reported by Jiang and coworkers
[24]. The FCGR2A-131H and FCGR2A-131R alleles were
visualized as 337 bp and 316 bp DNA fragments, respectively
(Fig. 1b). These genotyping findings were confirmed by direct
sequencing in some individuals.
Statistical analysis
The data were analyzed using the Student's t-test and the χ2
test, and Fisher's exact test was used when expected frequen-
cies were lower than 5. We used Mann–Whitney U-test to
evaluate the distribution of anti-GPI antibodies in FcγRIIIA-
158V/V RA patients and healthy individuals. P < 0.05 was
considered statistically significant.
Results
Our ELISA assay is highly specific because we used recom-
binant bacterial human GPI and native rabbit GPI, and double
positivity for the two antibodies correlated significantly with
the results of western blotting to GPI [18]. Because two GPI
antigens were used for discrimination, the cutoff value of the
OD was the mean value + one standard deviation from 158
healthy individuals, estimated using ELISA. Those who were
positive for both antibodies were considered to be anti-GPI
antibody positive. Using these definitions, 23 (12.3%) RA
patients were anti-GPI antibody positive, and nine (5.7%)
healthy individuals were anti-GPI antibody positive (Fig. 2).
Statistical analysis revealed a significant difference in anti-GPI
antibody positivity between RA patients and healthy individu-
als (χ2 = 4.438, with one degree of freedom; P = 0.0352).
To analyze whether functional FCGR polymorphisms were
correlated with anti-GPI antibody positive and negative individ-
uals, we performed FCGR genotyping. FCGR3A and
FCGR2A genotypes in the control group were in Hardy–
Weinberg equilibrium. The FCGR3A-158V allele (high affinity
genotype) was more frequently identified in patients with RA
than in healthy individuals within the anti-GPI antibody positive
population (χ2 = 0.012, with one degree of freedom; P =
0.012; Tables 1 and 2). In addition, these differences were evi-
dent when individuals were categorized according to the pres-
ence or absence of these genotypes: 56.5% of patients with
RA were homozygous or heterozygous with respect to
FCGR3A-158V, as compared with 11.1% of healthy individu-
als; and 43.5% of patients with RA were homozygous with
respect to FCGR3A-158F, as compared with 88.9% of
healthy individuals (χ2 = 5.42 with one degree of freedom; P <
0.02; Tables 1 and 2). Comparison of FCGR3A-158V allele
frequency between RA patients and healthy individuals
revealed no statistically significant difference: 48.7% of
patients with RA were homozygous or heterozygous with
respect to FCGR3A-158V, as compared with 42.4% of
healthy individuals; and 51.3% of patients with RA were
homozygous with respect to FCGR3A-158F, as compared
with 57.6% of healthy individuals (χ2 = 1.04 with one degree
of freedom; P = 0.245; Table 1).
Figure 1
PCR-RFLP analysis of the FCGR3A and FCGR2A genes. cDNA was 
amplified with primers and restriction digested using appropriate 
enzymes. Digested PCR products were visualized with ethidium bro-
mide. (a) FCGR3A gene and (b) FCGR2A gene. ND, nondigested 
PCR product; RE, restriction enzyme.
Figure 2
Population of anti-GPI antibody positive individuals, and FCGR3A and FCGR2A genotypes
FCGR2A genotypes. The study included 187 patients with rheumatoid 
arthritis and 158 healthy Japanese individuals. The horizontal and verti-
cal dotted lines represent the cutoff optical density values calculated 
from ELISA reactions of 158 healthy individuals for human recombinant 
GPI and rabbit native GPI, respectively. Individuals positive for both 
antibodies were considered anti-GPI antibody positive. Numbers in 
each graph represent the proportions of individuals positive for anti-GPI 
antibodies relative to the total number of individuals in that group. GPI, 
glucose-6-phosphate isomerase; HS, healthy subjects; RA, rheumatoid 
arthritis.
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(Table 1). In contrast to FCGR3A, the frequency of the
FCGR2A-131H allele (high affinity genotype) was not signifi-
cantly different between the two groups within the anti-GPI
antibody positive population (χ2 = 0.862 with one degree of
freedom; P = 0.35; Tables 1 and 2). These differences were
also not evident when individuals were categorized according
to the presence or absence of these genotypes (P = 0.19;
Tables 1 and 3).
We also analyzed the association between FcγR and other
related autoantibodies such as RF. There was no difference
between RF positive and RF negative populations of RA
patients (P = 0.82 and P = 0.4 for FCGR3A and FCGR2A,
respectively; Table 4).
Finally, in order to identify the relationship between FCGR3A-
158V allele and anti-GPI antibodies more clearly, we focused
on individuals who were homozygous for the high affinity
FCGR3A-158V/V genotype (14 RA patients and eight healthy
individuals) and compared their anti-GPI antibody titres.
Surprisingly, both anti-human GPI antibodies and anti-rabbit
GPI antibodies were significantly elevated in the RA group (P
= 0.0027 and P = 0.0015 for anti-human GPI antibodies and
anti-rabbit GPI antibodies, respectively, by Mann–Whitney U-
test; Fig. 3). This suggests that anti-GPI antibody positivity
Table 1
Frequencies of FCGR3A and FCGR2A genotypes in patients with RA and positive and negative for anti-GPI antibodies
FCGR3A-158 FCGR2A-131
FF low F/V VV high HH high H/R RR low
GPI+ RA (n = 23) 10 (43.5) 9 (39.1) 4 (17.4) 16 (69.6) 6 (26.1) 1 (4.3)
GPI- RA (n = 164) 86 (52.4) 68 (41.5) 10 (6.1) 128 (78) 29 (17.7) 7 (4.3)
GPI+ Control (n = 9) 8(88.9) 1 (11.1) 0 (0) 4 (44.4) 5 (55.6) 0 (0)
GPI- Control (n = 149) 83 (55.7) 58 (38.9) 8 (5.4) 109 (73.2) 40 (26.8) 0 (0)
Data are expressed as number (percentage) of individuals. GPI, glucose-6-phosphate isomerase; high, high affinity genotype; low, low affinity 
genotype; RA, rheumatoid arthritis.
Table 2
Alleic skewing of FCGR3A and FCGR2A in anti-GPI antibody positive healthy individuals
Polymorphism Allele RA GPI+ (n = 46) Healthy GPI+ (n = 18) P (χ2) P (Fisher's) OR (95% CI)
FCGR3A-158 F 29 17 0.012 0.013 0.10 (0.01–0.82)
V 17 1
FCGR2A-131 H 38 13 0.35 0.4902 1.83 (0.51–6.59)
R 8 5
P values are given for RA versus healthy individuals using a 2×2 contingency table. CI, confidence interval; Fisher's, Fisher's probability test; OR, 
odds ratio; RA, rheumatoid arthritis.
Table 3
Genotype skewing of FCGR3A and FCGR2A gene polymorphisms in anti-GPI antibody positive healthy individuals
Polymorphism Genotype RA GPI+ (n = 23) Healthy GPI+ (n = 9) P (χ2) P (Fisher's) OR (95% CI)
FCGR3A-158 FF 10 (43.5%) 8 (88.9%) 0.019 0.044 0.09 (0.01–0.89)
FV/VV 13(56.5%) 1 (11.1%)
FCGR2A-131 HH 16 (69.6%) 4(44.4%) 0.19 0.24 2.86 (0.58–13.96)
HR/RR 7 (30.4%) 5 (55.6%)
P values are given for RA versus healthy individuals using a 2×2 contingency table. CI, confidence interval; Fisher's, Fisher's probability test; OR, 
odds ratio; RA, rheumatoid arthritis.
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otype to arthritis.
Discussion
Several studies have indicated that anti-GPI antibodies are
potential arthritogenic antibodies [18-20] because they were
frequently detected in patients with severe forms of RA.
Because high titres of these antibodies (IgG, not IgM) were
also detected in healthy individuals, the arthritogenicity of
these antibodies should be due to modulation – by the low
affinity genotype of FcγRs – of the bypass between immune
complex and FcγR bearing cells. In a GPI immunized mouse
model severe arthritis occurred only in DBA/1 mice, although
the production of anti-GPI antibodies was almost equal in
arthritis susceptible and resistant mouse strains [25]. Thus,
the incidence of arthritis might depend on certain genetic fac-
tors such as FcγR. Anti-GPI antibody positive individuals
express several GPI variant mRNAs in peripheral blood mono-
cytes [26]. This observation supports the notion that the pres-
ence of GPI variants is necessary to produce anti-GPI
autoantibodies, and that genetic factors such as FcγRIIIA are
important in the development of arthritis. Based on this conclu-
sion, it is conceivable that the production of anti-GPI antibod-
ies does not occur as a 'result' of joint destruction.
Our results do not indicate that individual polymorphisms in
the FCGR3A and FCGR2A genes play roles in susceptibility
to RA. Despite the lack of association with individual FCGR
polymorphisms in the whole cohort, our studies suggest that
FCGR3A-158V/F polymorphisms play a crucial role in RA
among those individuals who are positive for anti-GPI antibod-
ies (Tables 2 and 3). Moreover, focusing on FCGR3A-158V/
V homozygous individuals, anti-GPI antibodies were clearly
evident in patients with RA. These findings suggest that anti-
GPI antibodies might have arthritogenic potential in individuals
homozygous for FCGR3A-158V/V.
Conclusion
Our findings show that FCGR3A-158V/F functional polymor-
phisms were associated with RA among anti-GPI antibody
positive individuals. This is the first report on possible mecha-
nisms of arthritic diseases; they are tightly regulated by some
genes, especially by FcγR genotype, as well as by production
of arthritogenic autoantibodies.
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